In addition, colony formation assay from CD34+ CML cells showed that the deletion of STAP-1 had the additive effects with imatinib in two out of six patients (Supplementary Fig. S4). The gene discussed is STAP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.